HOME ·

06185.HK

CANSINOBIO (06185.HK): Latest progress of mRNA technology platform, subsidiary signs co-development agreement for personalized therapeutic tumor vaccines
Tags：
CANSINOBIO06185.HKR&D Progress
2026-08-26
CANSINOBIO (06185.HK): Tetanus Vaccine Receives NMPA New Drug Application Approval, Expanding Adult Vaccine Market
Tags：
CANSINOBIO06185.HKR&D Progress
2026-08-20
CanSino Biologics (06185.HK): NDA for Td5cp, a Diphtheria-Tetanus-Pertussis Vaccine for Adolescents and Adults, Accepted for Review
Tags：
CanSino Biologics06185.HK
2026-08-16
CanSino Biologics (06185.HK): Supplementary Application for Menhyxin® Accepted, Age Eligibility to Be Expanded to 17 Years Old
Tags：
CanSino Biologics06185.HK
2026-07-19
CanSino Biologics (06185.HK): MCV4 Vaccine Granted Registration Certificate in Argentina
Tags：
CanSino Biologics06185.HK
2026-06-25
Cansinobio (06185.HK): Td5cp Vaccine for Adolescents & Adults Included in Priority Review
Tags：
CANSINOBIO06185.HKNew Drug Update
2026-05-11
CanSino Biologics Announces Clinical Trial Approval for PCV24 Vaccine in China
Tags：
CanSino Biologics Inc.06185.HK
2026-01-05